Free tool
FAERS Monitor: Relexxii
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216117 or its brand name (Relexxii, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
6,997
Serious
4,351
62% of reports
Hospitalization
1,710
Death reported
442
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,049
- headache399
- fatigue357
- anxiety352
- off label use340
- nausea333
- toxicity to various agents333
- product substitution issue290
- drug abuse285
- somnolence271
- insomnia265
- disturbance in attention240
- decreased appetite231
- suicidal ideation226
- agitation219
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 18 |
| 2010 | 14 |
| 2011 | 18 |
| 2012 | 69 |
| 2013 | 117 |
| 2014 | 121 |
| 2015 | 440 |
| 2016 | 343 |
| 2017 | 495 |
| 2018 | 576 |
| 2019 | 459 |
| 2020 | 352 |
| 2021 | 411 |
| 2022 | 611 |
| 2023 | 790 |
| 2024 | 744 |
| 2025 | 728 |
| 2026 | 676 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,162 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product substitution issueSignal | 290 | 15.2 | 13.6 | 3,828 |
| disturbance in attentionSignal | 240 | 13.4 | 11.9 | 2,744 |
| drug abuseSignal | 285 | 10.3 | 9.2 | 2,392 |
| agitationSignal | 219 | 9.0 | 7.9 | 1,548 |
| suicidal ideationSignal | 226 | 7.4 | 6.5 | 1,255 |
| toxicity to various agentsSignal | 333 | 5.9 | 5.4 | 1,373 |
| somnolenceSignal | 271 | 4.0 | 3.6 | 625 |
| anxietySignal | 352 | 3.7 | 3.4 | 706 |
| insomniaSignal | 265 | 3.0 | 2.7 | 354 |
| decreased appetiteSignal | 231 | 3.0 | 2.6 | 307 |
| drug ineffectiveSignal | 1,049 | 2.4 | 2.3 | 906 |
| headache | 399 | 1.9 | 1.7 | 178 |
| fatigue | 357 | 1.4 | 1.2 | 38 |
| nausea | 333 | 1.3 | 1.1 | 19 |
| off label use | 340 | 1.2 | 1.1 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.